Sugi Predict

Sugi Predict / Compounds / SCHEMBL1857142

SCHEMBL1857142

SCHEMBL1857142

CC(C)(C)OC(=O)N1CCc2c(cccc2C(=O)O)C1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ UCHL1 P09936 1/20 0.53
▸ ESR2 Q92731 1/20 0.53
▸ MAPK1 P28482 1/20 0.52
▸ NR1H2 P55055 1/20 0.52
▸ ADORA1 P30542 1/20 0.49
▸ SCN9A Q15858 1/20 0.48
▸ DDB1 Q16531 1/20 0.47
▸ CRBN Q96SW2 1/20 0.47
▸ ABHD6 Q9BV23 3/20 0.46
▸ NAMPT P43490 3/20 0.45
▸ PARP1 P09874 1/20 0.44
▸ TNKS2 Q9H2K2 1/20 0.44
▸ PARP2 Q9UGN5 1/20 0.44
▸ F12 P00748 2/20 0.44
▸ MAPT P10636 2/20 0.44
▸ LIPG Q9Y5X9 1/20 0.43
▸ KDM4E B2RXH2 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30647075 1.00 UCHL1 (0.53) UCHL1ESR2MAPK1NR1H2ADORA1
SCHEMBL29801280 0.91 ESR2 (0.54) UCHL1ESR2MAPK1NR1H2ADORA1
SCHEMBL1570606 0.91 ESR2 (0.54) UCHL1ESR2MAPK1NR1H2ADORA1
SCHEMBL21807308 0.90 UCHL1 (0.54) UCHL1ESR2MAPK1NR1H2ADORA1
SCHEMBL4787883 0.89 NR1H2 (0.54) UCHL1ESR2MAPK1NR1H2ADORA1
SCHEMBL29710389 0.88 DDB1 (0.53) UCHL1ESR2MAPK1NR1H2DDB1
SCHEMBL15893735 0.88 DDB1 (0.53) UCHL1ESR2MAPK1NR1H2DDB1
SCHEMBL16787750 0.86 MAPK1 (0.48) UCHL1ESR2MAPK1NR1H2ADORA1
SCHEMBL10197664 0.85 CARM1 (0.53) UCHL1ESR2MAPK1NR1H2SCN9A
SCHEMBL2122847 0.84 MAPK1 (0.50) UCHL1ESR2MAPK1NR1H2SCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12577243-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2026-03-17 — — US disclosed
EP-3856178-B1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2026-03-11 — — EP disclosed
CN-114507181-B Propionic acid compound containing 5-substituted tetrahydroisoquinoline, pharmaceutical composition and application thereof 中国医学科学院药物研究所 2024-03-26 — — CN disclosed
US-11820766-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2023-11-21 — — US disclosed
CN-108137542-B Pyridone dicarboxamides as bromodomain inhibitors 葛兰素史克知识产权第二有限公司 2023-10-27 — — CN disclosed
US-11648243-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2023-05-16 — — US disclosed
US-20230145249-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2023-05-11 — — US disclosed
EP-4144735-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS Array Biopharma, Inc. (US) 2023-03-08 — — EP disclosed
US-20220332713-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2022-10-20 — — US disclosed
US-20220313676-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA, INC. 2022-10-06 — — US disclosed
US-20080280876-A1 Novel oxadiazole compounds ABBVIE INC. 2008-11-13 — — US disclosed
WO-2008076356-A1 NOVEL OXADIAZOLE COMPOUNDS ABBOTT LABORATORIES (US) 2008-06-26 — — WO disclosed
WO-2008076356-A1 NOVEL OXADIAZOLE COMPOUNDS ABBOTT LABORATORIES (US) 2008-06-26 — — WO disclosed
US-20070259965-A1 Acyclic 1,3-Diamine And Uses Therefor SMITHKLINE BEECHAM CORPORATION 2007-11-08 — — US disclosed
EP-1797065-A2 ACYCLIC 1,3-DIAMINES AND USES THEREFOR SMITHKLINE BEECHAM CORPORATION (US) 2007-06-20 — — EP disclosed
US-20070117859-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2007-05-24 — — US disclosed
US-20070117859-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2007-05-24 — — US disclosed
US-7164019-B2 Such as cyclopentanecarboxylic acid {(S)-1-phenyl-3-[5-(pyridine-3-carbonyl)-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl]-propyl}-amide; antagonists of chemokine receptors, useful for treating/preventing human immunodeficiency virus infection, AIDS or ARC ROCHE PALO ALTO LLC (US) 2007-01-16 — — US disclosed
US-7164019-B2 Such as cyclopentanecarboxylic acid {(S)-1-phenyl-3-[5-(pyridine-3-carbonyl)-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl]-propyl}-amide; antagonists of chemokine receptors, useful for treating/preventing human immunodeficiency virus infection, AIDS or ARC ROCHE PALO ALTO LLC (US) 2007-01-16 — — US disclosed
WO-2006029210-A2 ACYCLIC 1,3-DIAMINES AND USES THEREFOR SMITHKLINE BEECHAM CORPORATION (US) 2006-03-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220332713-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP UCHL1 796/4885ESR2 963/4885MAPK1 4389/4885
US-12577243-B2 Monoacylglycerol lipase modulators MGLL, LPL, FAAH UCHL1 481/4885ESR2 1190/4885MAPK1 4010/4885
US-20230145249-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP UCHL1 796/4885ESR2 963/4885MAPK1 4389/4885
US-11648243-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 UCHL1 4486/4885ESR2 1364/4885MAPK1 65/4885
US-20080280876-A1 Novel oxadiazole compounds S1PR3, S1PR1, S1PR2 UCHL1 4871/4885ESR2 1423/4885MAPK1 2258/4885
US-20070259965-A1 Acyclic 1,3-Diamine And Uses Therefor TRPV4, TRPC4, TRPV1 UCHL1 3965/4885ESR2 2533/4885MAPK1 1428/4885
US-20220313676-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 UCHL1 4486/4885ESR2 1364/4885MAPK1 65/4885
US-11820766-B2 Monoacylglycerol lipase modulators MGLL, LPL, PNLIP UCHL1 796/4885ESR2 963/4885MAPK1 4389/4885
US-20070117859-A1 Heterocyclic antiviral compounds CCR5, ACKR3, CXCR1 UCHL1 4857/4885ESR2 1843/4885MAPK1 906/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.